Results 201 to 210 of about 228,118 (255)

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

Immunology &Cell Biology, EarlyView.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

Next-generation T cell engagers for cancer and autoimmune diseases. [PDF]

Front Immunol
Michaelson JS, Henry CC, Sauer K, Baeuerle PA.   +3 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective? [PDF]

Cancer Med
Wang L, Cao Y, Ren Y, Zhang Y, Wang L.
europepmc   +1 more source

Methionine Regulates Antitumour Function of CD8+ T Cells Through Polyamine Synthesis

Immunology, EarlyView.
Methionine restriction in vitro enhances CD8+ T cell effector function by suppressing polyamine synthesis and progressively induces the co‐expression of PD‐1 and TIM‐3. Consistently, sustained dietary methionine restriction diminishes the efficacy of adoptive T cell therapy (ACT) and promotes the expression of terminal exhaustion‐associated markers ...
Tian Zhao, Gillian A. Carleton, Sam Preshaw, Sarah MacPherson, Madison Shiyuk, Joseph Monaghan, Jun Han, Oro Uchenunu, Robert Rottapel, Ralph J. DeBerardinis, Kelly M. Stewart, Bo‐Hyun Kim, Juan Ausió, David R. Goodlett, Helena Pětrošová, Kyle D. Duncan, Julian J. Lum   +16 more
wiley   +1 more source

AI-Enforced Ultra-Large Virtual Screening Discovers Potent CD28 Binders. [PDF]

J Chem Inf Model
Upadhyay S, Roggia M, Yuan S, Cosconati S, Gabr MT.   +4 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

Immunology, EarlyView.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia, Emily Pauline Nickles, Yu Mei, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu, Rui Sun, Kang Yi Lee, Gloryn Chia, Chwee Ming Lim, Herbert Schwarz   +10 more
wiley   +1 more source

Treatment with saturating dose of conventional anti-CD28 monoclonal antibody well tolerated in pig acute myocardial infarction model. [PDF]

Front Immunol
Stadtmüller A, Grampp R, Marianantoni G, Schnitter F, Becker F, Nuriyeva K, Langenhorst D, Metka L, Günther K, Wiebusch L, Mair KH, Gladow N, Herrmann T, Rohr J, Hofmann U, Frey A, Beyersdorf N.   +16 more
europepmc   +1 more source

Genomic and proteomic insights into hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A dual pathogenic model of HS involving both epithelial dysfunction and systemic inflammation is supported. The HLA‐DRA association hints at autoimmune overlap, but the proteomic signature which is dominated by innate immune mediators favours an autoinflammatory classification, which may guide future therapeutic strategies and patient stratification ...
Maria Argyropoulou, Emmanouil Stylianakis, Isis Ricaño‐Ponce, Nick Keur, Theodora Kanni, Dimitra Stergianou, Mihai G. Netea, Vinod Kumar, Evangelos J. Giamarellos‐Bourboulis   +8 more
wiley   +1 more source

Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. [PDF]

Cancer Immunol Res
Tang E, Hu Y, Cao G, Nguyen DT, Asby NW, Aboelella NS, Ruiz HA, Cai X, Zhang W, Zhao Y, Xie L, Chen X, Bishop MR, Riedell PA, LaBelle JL, Kline JP, Huang J.   +16 more
europepmc   +1 more source